Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darunavir/ritonavir Once Daily in Treatment-Naive Adolescents
NCT00915655Phase 2Completed
- Sponsor
- Tibotec
- Start
- Jul 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of darunavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Tibotec. Primary endpoint: Virological Response (Viral Load < 50 copies/mL) at 24 weeks. Started Jul 2009; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00915655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00915655.